Advanced Liver Cancer Market

Advanced Liver Cancer Market Overview

The advanced liver cancer market is estimated to grow from USD 2.61 billion in 2024 to reach USD 2.99 billion in 2025 and USD 9.23 billion by 2035, representing a CAGR of 11.9% during the forecast period.

To learn more about this report, request a free sample copy

Given the rising incidence of liver cancer across the globe, a significant stride has been made by pharmaceutical companies in terms of drug development to improve patient outcomes. According to the stats of American Cancer Society, in 2025, around 42,240 new cases of liver cancer will be diagnosed in the U.S. The most common forms of liver cancer are intrahepatic bile duct cancer, metastatic or stage 4 liver cancer and hepatocellular carcinoma.

Notably, advanced liver cancer is a form of stage 4 liver cancer that spread in other areas of the body, such as blood vessels, lymph nodes and distant organs. Owing to the spreading nature, healthcare professionals are focusing on controlling diseases so patients can live a quality life.

To date, several immunotherapies, radiation therapies and targeted drug therapies are developed by the industrial players. Some of the notable first-line treatments include Sorafenib (Nexavar^®), Lenvatinib (Lenvima^®), Regorafenib (Stivarga^®), and Cabozantinib (Cabometyx^®).

Driven by the growing approval and necessity of drug demand for liver cancer, leading companies are focusing on the development of advanced drugs. However, the current focus is on the development of monoclonal antibody-based drugs, immune modulators and inhibitors to trigger immune response for targeting cancerous cells. It is important to highlight here that in March 2025, nivolumab (Opdivo^®) in combination with ipilimumab (Yervoy^®) has been approved by the European Commission for the frontline treatment of adult patients with advanced hepatocellular carcinoma (HCC). This approval was supported by the key findings from the Phase III 3 CheckMate 9DW trial (NCT04039607).  This combination received USFDA approval in April 2025.

Moreover, a recent study includes phase II clinical trial of tivozanib, a tyrosine kinase inhibitor in patients with advanced hepatocellular carcinoma that has demonstrated promising outcomes, including a 4-month progression-free survival (PFS) rate of 36.4% and a median overall survival (OS) of 12.2 months. Likewise, several therapeutic drugs are currently being evaluated under clinical pipelines for treating advanced hepatocellular carcinoma.

As more pharmaceutical players continue to focus on the development of targeted drugs, with artificial intelligence in advanced liver cancer treatment planning, we believe that advanced liver cancer market will grow at a steady pace during the forecast period.

Advanced Liver Cancer Market: Report Attributes

Key Report Attributes	Details
Historical Trend	Since 2020
Forecast Period	Till 2035
Market Size 2025	USD 2.99 Billion
Market Size 2035	USD 9.23 Billion
CAGR (Till 2035)	11.9%

One of the key objectives of the advanced liver cancer market report was to estimate the current size, opportunity, and the market growth potential, over the forecast period, till 2035. We have provided informed estimates on the likely evolution of the market for the forecast period.

The global market analysis report also features the likely distribution of the current and forecasted opportunity within the market across various segments, such as type of clinical trial, route of administration, type of molecule, mechanism of action, geographical regions and leading players.

In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three advanced liver cancer market forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of industry’s evolution.

Recent Developments in Advanced Liver Cancer Market

Several recent developments in the field of advanced liver cancer have occurred, and we outline some of these below.

• In March 2025, toripalimab (Loqtorzi^®) in combination with bevacizumab (Avastin^®) has been approved by the China’s National Medical Products Administration to treat patients with metastatic hepatocellular carcinoma.
• In March 2025, the FDA initiated a second complete response letter (CRL) to camrelizumab in combination with rivoceranib as the first line of treatment to treat patients with metastatic hepatocellular carcinoma.
• In February 2025, Amezalpat^®, an oral, small molecule, selective PRARα antagonist received fast track designation by the FDA to treat patients with hepatocellular carcinoma. Data from the phase Ib / 2 MORPHEUS-Liver trial supported the fast-track designation.

Recent Breakthrough Treatment of Advanced Liver Cancer

Currently, several therapeutics drugs for targeting advanced liver cancer are currently being investigated under clinical trials. Among these several researchers have shown positive outcomes in treating patients with hepatocellular carcinoma.

Recent research published by researchers at Mount Sinai in January 2025, led by Josep M. Llovet, MD, PhD, Professor of Medicine (Liver Diseases) at the Icahn School of Medicine at Mount Sinai have made a breakthrough in the treatment of hepatocellular carcinoma with combination approach. Under Phase III clinical study, “LEAP-012: Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma,” has shown a significant improvement in patients.

Advanced Liver Cancer Market Segmentation Insights

The market report provides comprehensive information on advanced liver cancer treatment developers who are currently active across various segments of the industry as mentioned in the table below.

Advanced Liver Cancer Market: Market Segmentation

Market Segmentations	Details
Phase of Clinical Trial	Phase III Phase II Phase I
Route of Administration	Oral Intravenous
Type of Molecule	Small Molecule Monoclonal Antibody
Mechanism of Action	Adenosine Receptor Agonist Immune Modulator Arginine Deprivation
Geographical Regions	North America Europe Asia-Pacific Middle East and North Africa Latin America
Market in North America	US Canada Mexico
Market in Europe	France Germany Italy Spain UK Rest of Europe
Market in Asia-Pacific	China India Japan South Korea Rest of the Asia-Pacific
Market in Middle East and North Africa	Egypt Saudi Arabia United Arab Emirates
Market in Latin America	Argentina Brazil

Industry Experts on Advanced Liver Cancer Market

Key market players, such as Abbott, Bayer and Roche are continually emphasizing on the development of novel drugs and strengthening their product portfolio.

CheckMate-9DW study investigator, Aiwu Ruth He, MedStar Georgetown University Hospital, said: “The availability of a new first-line treatment option, such as Opdivo^® (nivolumab) plus Yervoy^® (ipilimumab) demonstrated a deep response can offer adults with this form of liver cancer long-term overall survival and may help address an unmet need”.

Advanced Liver Cancer Market Share Insights

Market Share by Phase of Clinical Trial: Phase III Segment Holds the Highest Share

• Based on the phase of clinical trial, the global market is segmented into Phase III, Phase II and Phase I. According to the advanced liver cancer market report, presently Phase III segment holds the largest share (nearly 50%) of the market. This is potentially due to the rising regulatory designation to the drugs under Phase III trial. Furthermore, the pharmaceutical companies are also expanding their research to prioritize the approval chances of Phase III drugs.
• It is worth mentioning that the rising number of volunteers enrollments for Phase III trials and promising outcomes of the trials are the robust reason for dominance in this region. Driven by the promising outcomes, this segment is likely to register a higher CAGR over the forecast period.

Market Share by Route of Administration: Oral Drugs Segment Holds the Largest Share

• The global market is segmented across different routes of administration, such as oral and intravenous. According to the advanced liver cancer market analysis, currently oral segment holds the majority of share (nearly 55%) driven by the high patient preference for oral drugs. Furthermore, majority of the USFDA approved drugs are available in oral dosage form so patients can easily administer them.
• It is worth mentioning that oral dosing can be self-administered which reduces burden from healthcare system for drug delivery. Driven by the preferences of oral drugs, this segment is anticipated to grow at a significant CAGR during the forecast period.

Market Share by Type of Molecule: Small Molecules Occupy the Highest Share

• The global market is categorized across type of molecule, such as small molecule, and monoclonal antibody. Currently, small molecule segment is dominating the market by holding the largest advanced liver cancer market share. This can be attributed to the growing approval of targeted small molecules to target cancerous cells at cellular signaling pathway level.
• It is worth mentioning that this segment is expected to remain dominant and likely to register a higher CAGR during the forecast period. This is likely to be the result of expanding research on small molecules to target disease related protein targets.

Market Share by Mechanism of Action: Immune Modulator Holds the Largest Share

• The advanced liver cancer market analysis is bifurcated into adenosine receptor agonist, immune modulator, and arginine deprivation. It is worth mentioning that immune modulators currently hold the highest market share. This can be attributed to the increasing approval of immune modulators in combinations with targeted antibodies has been approved as the first-line treatment to treat advanced hepatocellular carcinoma patients.
• Additionally, the ongoing research on immune modulators, including immune checkpoint inhibitors, and rising approval of the drugs are key reason for highest share. Owing to the increasing research, this segment will continue to grow at a higher CAGR during the forecast period.

Market Share by Geographical Regions: North America Holds the Largest Share

• The global market is distributed across different regions, such as North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. Among these, presently North America is holding the highest share of the advanced liver cancer market. This is likely to be the result of the growing incidence of advanced liver cancer and rising research on cancer treatment.
• In Asia-Pacific, the market for advanced liver cancer is expected to grow at a higher CAGR during the forecast period. The growing focus on cancer research and government initiatives to mitigate the growing concern of liver cancer in this region are the key factors for lucrative growth.

Advanced Liver Cancer Market: Report Deliverables

Report Deliverables	Details
Excel Data Packs (Complimentary)	Available
Key Drug Developers Profiled	Adagene Abbisko Therapeutics Binhui Biopharmaceutical Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Jiangsu Hengrui Pharmaceutical Jennerex Biotherapeutics Mina Alpha Mayo Clinic Qilu Pharmaceutical Roche Sanofi Tempest Therapeutics (A complete list of companies captured is available in the report)
PowerPoint Presentation (Complimentary)	Available
Customization Scope	15% Free Customization

Advanced Liver Cancer Market Major Takeaways

The “Advanced Liver Cancer Market: Industry Trends and Global Forecasts, till 2035” market report features an extensive study of the current market landscape, market size, market share, market growth, market trends, market value, market forecast, market outlook, statistics, and future opportunities for the drug developers in advanced liver cancer industry. The market research report lays emphasis on the advanced liver cancer drugs that are being developed. Key takeaways of the market report are briefly discussed below.

Competitive Landscape of Advanced Liver Cancer Market

Presently, the global market for advanced liver cancer is highly fragmented, featuring the presence of well-established and new entrants. Market players, such as Abbott, Bayer, Siemens Healthineers, and Roche continue to develop novel drugs and advanced imaging technologies to enhance patient outcomes.

Furthermore, the players are focusing on identifying biomarkers, first-line therapy, second-line treatment options and inhibitor-based drugs that can inhibit the cancerous cells growth. As more market players continue to proliferate their efforts in this field, we believe that the advanced liver cancer industry will remain competitive during the forecast period.

Market Size Analysis: Advanced Liver Cancer Market

Market size for advanced liver cancer therapeutics is estimated to reach USD 9.23 billion by 2035, driven by the recent launch of combination treatment of Opdivo and Yervoy in the US and EU, as well sNDA approval of combination of Junshi Biosciences’ TUOYI^® (toripalimab) and bevacizumab in China in March 2025. The market stands to grow at a CAGR of 11.9% during the forecast period.

Currently, the market lacks treatment options for patients with advanced liver cancer. Majority patients are diagnosed at advanced stages. However, a number of companies are working on the development of liquid biopsy tests for early detection of liver cancer, which is likely to limit the growth of the market during the latter half of the forecast period.

Market Drivers: What are the Key Drivers of the Advanced Liver Cancer Market?

Rising Incidence of Liver Cancer and Accelerated Approval Pathway

Growing incidence of liver cancer or metastatic liver cancer necessitated the demand for targeted therapies to treat patients. Furthermore, accelerated approval pathways from regulatory agencies to approve targeted therapies further propel the market growth during the forecast period. Additionally, advanced early cancer detection technologies have offered enormous opportunities to the players for designing first-line treatment for the patients.

Market Challenges: What are the Major Advanced Liver Cancer Market Challenges?

High Cost, Drug Resistance and Side Effects

The market for advanced liver cancer is hindered by several factors. Some of these factors are the high cost of cancer therapeutics, high drug resistance and side effects. It is worth mentioning that the high cost of advanced liver cancer therapies may limit its accessibility in low to middle income, which in turn affects market growth. Additionally, the development of drug resistance due to continuous usage may create challenges in the treatment of patients with liver cancer. Moreover, the side effects associated with advanced liver cancer therapies may limit their adoption by healthcare practitioners.

Market Trends: What are the Key Opportunities in the Advanced Liver Cancer Market?

Combination Therapies for Metastatic Liver Cancer and Personalized Therapies

In order to enhance treatment efficacy, several market players are aiming for designing combination drugs and personalized therapies. For instance, Atezolizumab (Tecentriq^®) and bevacizumab (Avastin^®) are recently approved first-line treatment by the FDA for the treatment of advanced liver cancer specifically those cannot be removed by surgically. Notably, Atezolizumab (Tecentriq^®) is an immunotherapy agent the directly blocks the PD-L1 pathway (a protein used by cancer cells to evade the immune system).

Furthermore, the growing shift towards personalized medicine to target advanced liver cancer is offering new opportunities to the industrial players. Moreover, the key focus will be first-line and second-line treatment options to improve patient outcomes. In addition to therapeutic treatment, industrial players are also focusing on biomarker-driven strategies to overcome the risk of drug resistance and side effects.

Major Partnerships and Breakthroughs in Advanced Liver Cancer Market

With increasing focus on targeted therapies for advanced liver cancer, several industrial players are leveraging partnerships and collaborations. For instance, in May 2025, Firstgene Life Sciences and Hovione announced a strategic collaboration to advance Hovione’s proprietary virus-like particle drug delivery platform for targeting treatment of hepatocellular carcinoma.

In addition to partnerships, several breakthroughs have been noticed in the industry. For instance, in January 2025, NiKang Therapeutics, announced that first patient has received dosage in global randomized Phase 1b / 2 clinical study evaluating a highly potent orally bioavailable small molecule HIF2α inhibitor in combination with atezolizumab (Tecentriq^®) and bevacizumab (Avastin^®) in the first-line treatment of patients having advanced or metastatic hepatocellular cancer.

Advanced Liver Cancer Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various stakeholders in the advanced liver cancer industry, across different geographies. Amongst other elements, the market report includes:

• An Infographic Executive Summary
• Market Landscape of Advanced Liver Cancer Treatment Developers
• Company Competitiveness Analysis
• Company Profiles
• SWOT Analysis
• Market Impact Analysis
• Market Forecast Analysis

From the Author’s Desk

Author’s View on Advanced Liver Cancer Treatment Market

The advanced liver cancer treatment industry is likely to experience a remarkable growth in the upcoming years. The key factors that are accelerating industry growth include rising clinical pipelines, expanding research, and approval of targeted therapies. Furthermore, industrial players are aiming to follow a combinational approach and leveraging partnerships, which is expected to drive this industry during the forecast period.

Glossary

• Advanced Liver Cancer: It refers to malignant hepatic tumors that have spread either beyond the liver to lymph nodes or other organs or have reached a stage where surgical removal of cancer growth is not possible.
• Metastasis Liver Cancer: It is a form of cancer that originated in another part of the body and subsequently spread to the liver via the bloodstream or lymphatic system. This type occurs more frequently than primary liver cancer that has metastasized.
• Immune inhibitors: These are specialized immune checkpoint inhibitors (type of immunotherapy) that work by blocking proteins called checkpoints, which are normally used by the immune system to regulate its response. Immune Inhibitors, such as PD-1 and PD-L1 inhibitors, prevent immune cells from being "turned off" too early, allowing them to better target and attack cancer cells.